Methotrexate and cytarabine-based chemotherapy in primary central nervous system lymphoma


  • Systemic and intraventricular methotrexate (MTX) and cytarabine (AraC)-based chemotherapy is associated with long-term disease control in people with primary central nervous system lymphoma (PCNSL), particularly those aged ≤60 years.

Why this matters

    This study provides evidence that MTX-based polychemotherapy may offer long-term benefits and increase the chance of survival in people with PCNSL.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.